Back

Spatial expression of an mRNA encoding Tie2-agonist in the capillary endothelium of the lung prevents pulmonary vascular leakage

Radloff, K.; Gutbier, B.; Dunne, C. M.; Moradian, H.; Gossen, M.; Ahrens, K. M.; Kneller, L.; Wang, Y.; Moga, A.; Gkionis, L.; Keil, O.; Fehring, V.; Tondera, D.; Giese, K.; Santel, A.; Kaufmann, J.; Witzenrath, M.

2022-11-25 molecular biology
10.1101/2022.10.12.511878 bioRxiv
Show abstract

Angiopoietin ligands Ang1 and Ang2 and the Tie2 receptor tyrosine kinases form an endothelial signaling pathway regulating vascular homeostasis and controlling vessel permeability, inflammation and angiogenic responses. Whereas Ang1-mediated Tie2 activation reduces inflammation and endothelial permeability, its antagonist, Ang2 increases it. Increased plasma Ang2 levels are associated with poor outcomes in patients with acute lung injury (ALI), as well as in acute respiratory distress syndrome (ARDS). In the study presented here we tested the effect of a novel synthetic, nucleoside-modified mRNA-76 encoding for a hyperactive Ang1 derived fusion protein (COMP-Ang1) on attenuating post-inflammation vascular leakage. COMP-Ang1 mRNA was formulated into a cationic lipid nanoparticle (cLNP) using an optimized mixture of three different lipids and a microfluidic mixing technology. After intravenous injection, the respective mRNA-loaded LNPs were found to be delivered predominantly to the endothelial cells of the lung, while sparing other vascular beds. Also, the specific multimeric folding of the COMP-Ang1 protein complex appeared to be pivotal for its activity in preventing vascular leakage and in restoring the alveolar-endothelial barrier function in the inflamed and injured pulmonary vasculature. The mode of action of mRNA-76, such as its activation of the Tie2 signal transduction pathway, was tested by pharmacological studies in vitro and in vivo by systemic administration in respective mouse models. mRNA-76 was found to prevent lung vascular leakage/lung edema as well as neutrophil infiltration in an LPS-challenging model.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

1
Journal of Controlled Release
39 papers in training set
Top 0.1%
42.6%
2
International Journal of Molecular Sciences
453 papers in training set
Top 2%
3.9%
3
Scientific Reports
3102 papers in training set
Top 32%
3.9%
50% of probability mass above
4
Nature Communications
4913 papers in training set
Top 44%
2.6%
5
PLOS ONE
4510 papers in training set
Top 47%
2.2%
6
Biomaterials
78 papers in training set
Top 0.4%
1.9%
7
iScience
1063 papers in training set
Top 17%
1.6%
8
Molecular Therapy
71 papers in training set
Top 2%
1.4%
9
Arteriosclerosis, Thrombosis, and Vascular Biology
65 papers in training set
Top 1%
1.3%
10
Molecular Therapy Nucleic Acids
32 papers in training set
Top 0.5%
1.0%
11
Advanced Science
249 papers in training set
Top 15%
1.0%
12
ACS Omega
90 papers in training set
Top 3%
1.0%
13
Advanced Materials
53 papers in training set
Top 1%
1.0%
14
Advanced Therapeutics
15 papers in training set
Top 0.4%
0.9%
15
ACS Applied Bio Materials
21 papers in training set
Top 0.7%
0.9%
16
Small
70 papers in training set
Top 1.0%
0.9%
17
Biomedicines
66 papers in training set
Top 2%
0.9%
18
ACS Nano
99 papers in training set
Top 3%
0.8%
19
Frontiers in Bioengineering and Biotechnology
88 papers in training set
Top 2%
0.8%
20
Molecular Therapy - Nucleic Acids
24 papers in training set
Top 0.3%
0.8%
21
Biomaterials Advances
20 papers in training set
Top 0.6%
0.8%
22
Biomaterials Science
21 papers in training set
Top 0.5%
0.8%
23
Cell Proliferation
12 papers in training set
Top 0.3%
0.8%
24
Journal of Extracellular Biology
18 papers in training set
Top 0.1%
0.8%
25
Nano Letters
63 papers in training set
Top 3%
0.8%
26
Circulation
66 papers in training set
Top 2%
0.8%
27
Biomedicine & Pharmacotherapy
43 papers in training set
Top 1%
0.8%
28
Pharmaceutics
21 papers in training set
Top 0.4%
0.8%
29
Bioactive Materials
18 papers in training set
Top 0.7%
0.8%
30
Journal of Nanobiotechnology
10 papers in training set
Top 0.3%
0.7%